

North Central Cancer Treatment Group

N0871: A Phase II Study of Carboplatin (CBDCA), Paclitaxel (TAXOL), and Everolimus (RAD001) in Previously Untreated Patients with Measureable Disease with Cancer of Unknown Primary (CUP)

Status Change Notice – September 21, 2011

NOTICE OF STATUS CHANGE

Due to a shortage of drug supply for RAD001, this study is temporarily closed to patient accrual effective Wednesday, September 21, 2011.

Patients currently on study will be able to continue treatment, but drug re-supply will be limited to a 30 day supply at a time for each patient. Patients that have already been consented, but have not started therapy, will be able to receive treatment.

Please retain this notice with the protocol.